Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.47 |
| ▸ | BRAF | P15056 | 13/20 | 0.41 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | BCR | P11274 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | RARG | P13631 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366948 | 0.92 | KDR (0.48) | KDRBRAFKITPDGFRARIPK2 | |
| SCHEMBL3366914 | 0.91 | KDR (0.56) | KDRBRAFKITPDGFRARIPK2 | |
| SCHEMBL13363760 | 0.89 | KDR (0.46) | KDRBRAF | |
| SCHEMBL13363770 | 0.86 | KDR (0.44) | KDRBRAFKITTEK | |
| SCHEMBL13363759 | 0.86 | KDR (0.53) | KDRBRAFKITPDGFRARIPK2 | |
| SCHEMBL13363778 | 0.86 | KDR (0.47) | KDRBRAFKITRAF1 | |
| SCHEMBL6473395 | 0.86 | RAF1 (0.46) | KDRBRAFKITPDGFRARIPK2 | |
| SCHEMBL13790304 | 0.85 | KDR (0.51) | KDRBRAFKITPDGFRARIPK2 | |
| SCHEMBL13799389 | 0.85 | KDR (0.46) | KDRBRAFKITPDGFRARIPK2 | |
| SCHEMBL13363761 | 0.85 | KDR (0.45) | KDRBRAFKITRAF1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076488-B2 | Antiproliferative agents; angiogenesis inhibitors; anticancer agents | BAYER HEALTHCARE LLC (US) | 2011-12-13 | — | — | US | disclosed |
| EP-1599467-B1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER HEALTHCARE LLC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-7557129-B2 | Cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557129-B2 | Cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC (US) | 2009-07-07 | — | — | US | disclosed |
| US-20050038031-A1 | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038031-A1 | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | CCNC, UACA, SLC14A1 | KDR 502/4885BRAF 501/4885KIT 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.